ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$162.92
+1.90%Next report
Analyst consensus
- Next report date
- Feb 11, 2027
- EPS estimate
- $1.72
- Revenue estimate
- $1.5B
Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- $16
- EPS estimate
- $1.66
- Revenue actual
- $1.5B
- Revenue estimate
- $1.5B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +224.4%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $303
- PT range
- $199 – $455
- Analysts
- 17
12 Buy5 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | $1.66 | $16 | Beat 879.52% | $1.5B |
| Jul 30, 2026 | $1.63 | $1.21 | Miss -25.77% | $1.3B |
| Apr 30, 2026 | $0.87 | $1.51 | Beat 73.17% | $1.2B |
| Feb 12, 2026 | $1.16 | $0.82 | Miss -29.31% | $1.1B |
| Oct 30, 2025 | $0.56 | $2.90 | Beat 416.93% | $1.2B |
| Jul 31, 2025 | -$0.54 | $0.32 | Beat 158.85% | $773.7M |
| May 1, 2025 | -$0.89 | -$0.01 | Beat 98.88% | $594.2M |
| Feb 13, 2025 | -$0.62 | $0.06 | Beat 109.68% | $593.2M |
| Oct 31, 2024 | -$0.92 | -$0.50 | Beat 45.45% | $500.9M |
| Aug 1, 2024 | -$1.07 | $0.56 | Beat 152.34% | $659.8M |
| May 2, 2024 | -$1.12 | -$0.16 | Beat 85.71% | $494.3M |
| Feb 15, 2024 | -$1.20 | -$1.10 | Beat 8.33% | $439.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 11, 2027